These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

904 related articles for article (PubMed ID: 31057295)

  • 1. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
    Rozengurt E; Eibl G
    World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops.
    Eibl G; Rozengurt E
    Semin Cancer Biol; 2019 Feb; 54():50-62. PubMed ID: 29079305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
    Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis.
    Morvaridi S; Dhall D; Greene MI; Pandol SJ; Wang Q
    Sci Rep; 2015 Nov; 5():16759. PubMed ID: 26567630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice.
    Hao F; Xu Q; Wang J; Yu S; Chang HH; Sinnett-Smith J; Eibl G; Rozengurt E
    PLoS One; 2019; 14(5):e0216603. PubMed ID: 31100067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating β-Catenin
    Gao C; Chen G; Zhang DH; Zhang J; Kuan SF; Hu W; Esni F; Gao X; Guan JL; Chu E; Hu J
    Cell Mol Gastroenterol Hepatol; 2019; 8(4):561-578. PubMed ID: 31330317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.
    Zhang W; Nandakumar N; Shi Y; Manzano M; Smith A; Graham G; Gupta S; Vietsch EE; Laughlin SZ; Wadhwa M; Chetram M; Joshi M; Wang F; Kallakury B; Toretsky J; Wellstein A; Yi C
    Sci Signal; 2014 May; 7(324):ra42. PubMed ID: 24803537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.
    Strnadel J; Choi S; Fujimura K; Wang H; Zhang W; Wyse M; Wright T; Gross E; Peinado C; Park HW; Bui J; Kelber J; Bouvet M; Guan KL; Klemke RL
    Cancer Res; 2017 Apr; 77(8):1997-2007. PubMed ID: 28381547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
    Chen M; Wang M; Xu S; Guo X; Jiang J
    Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling.
    Gruber R; Panayiotou R; Nye E; Spencer-Dene B; Stamp G; Behrens A
    Gastroenterology; 2016 Sep; 151(3):526-39. PubMed ID: 27215660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma.
    Zhao C; Gong J; Bai Y; Yin T; Zhou M; Pan S; Liu Y; Gao Y; Zhang Z; Shi Y; Zhu F; Zhang H; Wang M; Qin R
    Cell Death Differ; 2023 Jan; 30(1):1-15. PubMed ID: 35906484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
    Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
    Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma.
    Hayashi H; Uemura N; Zhao L; Matsumura K; Sato H; Shiraishi Y; Baba H
    Front Oncol; 2021; 11():700315. PubMed ID: 34395269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YAP/TAZ for cancer therapy: opportunities and challenges (review).
    Guo L; Teng L
    Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
    Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
    Zhu J; Wu T; Lin Q
    Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.
    Murakami S; Shahbazian D; Surana R; Zhang W; Chen H; Graham GT; White SM; Weiner LM; Yi C
    Oncogene; 2017 Mar; 36(9):1232-1244. PubMed ID: 27546622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.
    Wang MT; Fer N; Galeas J; Collisson EA; Kim SE; Sharib J; McCormick F
    Nat Commun; 2019 Jul; 10(1):3055. PubMed ID: 31296870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.